Rutgers Cancer Institute of New Jersey Joins OncLive Strategic Alliance Partnership Program

Published: Tuesday, Feb 10, 2015
PLAINSBORO, N.J. (Feb. 10, 2015) – OncLive® today welcomes Rutgers Cancer Institute of New Jerseyas a partnerin promoting awareness of the most recent advances in cancer care through OncLive’s Strategic Alliance Partnership program.

In the new partnership, OncLive’s editorial and marketing teams will publicize important news from Rutgers Cancer Institute of New Jersey, where distinguished researchers and clinicians worktogether to improve the prevention, detection, treatment and care of patients with cancer. Rutgers Cancer Institute of New Jersey is designated by the National Cancer Institute as the state’s only Comprehensive Cancer Center for its scientific excellence and capacity to combine multiple research approachestotackle cancer comprehensively.

Mike J. Hennessy Jr., senior vice president, oncology & specialty pharmacy, which includes OncLive, said, “We are honored to partner with Rutgers Cancer Institute of New Jersey to spread the word about new developments in cancer research and care. Whenever there is an organization like the Cancer Institute of New Jersey making discoveries and providing the latest medicines and most advanced treatment options to patients, real potential exists to inspire other institutions by sharing the stories behind those accomplishments.”

Robert S. DiPaola, M.D., director of Rutgers Cancer Institute of New Jersey, said, “We are committed to providing patients with a compassionate team of experts and the most advanced cancer care available, including access to clinical trials available only at NCI-designated Cancer Centers like ours.We collaborate broadly across our state and the country and we look forward to enhancing that reach by creating more dialogue about the latest in cancer care through OncLive’s Strategic Alliance Partnership program.”

Rutgers Cancer Institute of New Jersey joins more than 30 other leading cancer centers, nursing schools and physician groups around the country in partnering with OncLive.

Hennessy added, “This partnership and the broader Strategic Alliance benefits everyone dedicated to the fight against cancer. Collaborating, sharing information and working togetherincreases our chances of finding the most powerful ways to combat this disease.”

About OncLive is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. OncLive offers oncology professionals resources and information to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research, and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, N.J. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable.Its flagship product is CURETM ggggmagazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers, and advocacy groups. To learn more, please visit

About Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey ( is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, the Cancer Institute of New Jersey is dedicated to improving the detection, treatment and care of patients with cancer and to serving as an educationresource for cancer prevention. Physician-scientists at the Cancer Institute engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life.Follow the Instituteon Facebook at


Media Contacts:

For Cancer Institute of New Jersey: Michele Fisher, 732-235-9872,

For OncLive:Becky Taylor, 609-240-6886,

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication